1. Home
  2. VERU vs MKTW Comparison

VERU vs MKTW Comparison

Compare VERU & MKTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.99

Market Cap

48.2M

Sector

Health Care

ML Signal

HOLD

Logo MarketWise Inc.

MKTW

MarketWise Inc.

HOLD

Current Price

$16.81

Market Cap

39.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERU
MKTW
Founded
1971
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
48.2M
39.7M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
VERU
MKTW
Price
$2.99
$16.81
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$22.50
$20.00
AVG Volume (30 Days)
5.2M
11.3K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
10.20%
EPS Growth
N/A
1183.33
EPS
N/A
N/A
Revenue
$16,296,958.00
$512,403,000.00
Revenue This Year
N/A
$1.52
Revenue Next Year
N/A
$4.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$13.49
52 Week High
$7.33
$21.74

Technical Indicators

Market Signals
Indicator
VERU
MKTW
Relative Strength Index (RSI) 54.10 44.94
Support Level $2.11 $16.17
Resistance Level $4.57 $17.69
Average True Range (ATR) 0.25 0.58
MACD -0.03 0.00
Stochastic Oscillator 28.68 16.97

Price Performance

Historical Comparison
VERU
MKTW

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

Share on Social Networks: